Authors' response to Almirall *et al*

Almirall *et al* have reanalysed their previously published data¹ (that we have previously critiqued²) and shown that benzodiazepine exposure is associated with a reduced risk of pneumonia in younger patients.³ They report both bivariate and multivariate analyses³ but, by contrast with our analysis⁴ have only adjusted for a few comorbidities. For example, it is unclear why they have adjusted for temperature change, that is presumably a consequence of the outcome of interest: pneumonia. The biological rationale for their finding is also unclear, the authors justify their data by suggesting that REM sleep depression may reduce the incidence of bronchial aspiration. Critically, they ignore data that REM sleep deprivation leads to disordered thermogenesis and increased mortality⁵; in addition to data showing direct impairments of immune function by benzodiazepines.⁶ While we acknowledge the limitations of our data⁴ that depend on the clinical diagnosis of lower respiratory tract infection, this may lend generalisability to clinicians as a readily diagnosed endpoint.⁴ If present, misclassification of benzodiazepine exposure would likely shift the data towards unity; however, we observed a clinically important risk of both pneumonia and death from

pneumonia, reducing concerns over this issue.⁴ This is paralleled by our basic science investigations that demonstrate increased mortality from *Streptococcus pneumoniae*⁶ and other studies showing increased mortality to other pathogens.⁷ Nonetheless, we acknowledge the limitations of database studies and argue that prospective cohort and randomised controlled trials are definitely required. Though we stress that meta-analysis of randomised controlled trials of eszopiclone, remelteon, zalepon and zolpidem suggest a similar vulnerability to infection⁸ as we discovered in our analysis of data with benzodiazepines and the non-benzodiazepine zopiclone.⁴

Robert D Sanders

Correspondence to Dr Robert D Sanders, Wellcome Department of Imaging Neuroscience, University College London & Department of Anaesthesia & Surgical Outcomes Research Centre, University College London Hospital, London SW10 9NH, UK; r.sanders@ucl.ac.uk

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Sanders RD. *Thorax* 2013;**68**:965–966.

Received 8 April 2013

Accepted 9 April 2013

Published Online First 9 May 2013

► <http://dx.doi.org/10.1136/thoraxjnl-2013-203634>

Thorax 2013;**68**:965–966.

doi:10.1136/thoraxjnl-2013-203701

REFERENCES

- 1 Almirall J, Bolibar I, Balanzo X, *et al*. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. *Eur Respir J* 1999;13:349–55.
- 2 Amarasuriya UK, Myles PR, Sanders RD. Long-term benzodiazepine use and mortality: are we doing the right studies? *Curr Drug Saf* 2012;7:367–71.
- 3 Almirall J, Serra-Prat M, Baron F, *et al*. The use of benzodiazepines could be a protective factor for community-acquired pneumonia (CAP) in ≤ 60-year-old subjects. *Thorax* Published Online First: doi:10.1136/thoraxjnl-2013-203634
- 4 Obiora E, Hubbard R, Sanders RD, *et al*. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. *Thorax* 2013;**68**:163–70.
- 5 Rechtschaffen A, Bergmann BM, Everson CA, *et al*. Sleep deprivation in the rat: X. Integration and discussion of the findings. 1989. *Sleep* 2002;25:68–87.
- 6 Sanders RD, Godlee A, Fujimori T, *et al*. Benzodiazepine augmented γ -amino-butyric acid signaling increases mortality from pneumonia in mice. *Crit Care Med* Published Online First: 8 March 2013. doi: 10.1097/CCM.0b013e31827c0c8d
- 7 Sanders RD, Hussell T, Maze M. Sedation & immunomodulation. *Crit Care Clin* 2009;25:551–70, ix.

- 8 Joya FL, Kripke DF, Loving RT, *et al*. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. *J Clin Sleep Med* 2009;5:377–83.